Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Lakefront Biotherapeutics West LLC
OM336 is an engineered bispecific antibody that binds BCMA and CD3. It is being studied in Sjogren's disease and idiopathic inflammatory myopathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07229144 | Phase 1 | Sjogrens Disease | Recruiting | LKFT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Inflammatory Myopathy (IIM)Sjogrens Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.
See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LKFT catalysts and pipeline →